Daniel L. Kisner, M.d.
United States of America
Dr. Daniel Kisner has served as one of our directors since August 2015. Dr. Kisner currently serves as a consultant to the pharmaceutical/biotech industry. From 2003-2011 he served as a venture partner/partner at Aberdare Ventures. Prior to that he was President and Chief Executive Officer of Caliper Technologies from 1999 and remained Chairman until 2008. He led Caliper from a startup dealing with microfluidic lab-on-a-chip technology to a publically traded commercial company. From 1991 until 1999 He served as COO and president of Isis Pharmaceuticals, a biomedical pharmaceutical company. Previously, Dr. Kisner was Division Vice President of Pharmaceutical Development at Abbott Laboratories and Vice President of Clinical Research at SmithKline Beckman Laboratories. In addition he previously held a tenured position at the University of Texas School of Medicine at San Antonio and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Dr. Kisner currently serves on several boards of directors including those of Dynavax Technologies, Lpath Pharmaceuticals and Conatus Pharmaceuticals. He holds a B.A. degree from Rutgers University and an M.D. from Georgetown University.
At Zynerba Pharmaceuticals, we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs.